ArcticZymes Technologies
Mindre end 1K følgere
AZT
Oslo Børs
Biotechnology & Pharmaceuticals
Health Care
Oversigt
Investorkonsensus
ArcticZymes Technologies is active in biotechnology. The company specializes in research and development of drugs for the treatment of autoimmune diseases. The main focus is on the development of glucans, the production of immunostimulants, and the analysis of enzymes. The vision is to test and develop the medicine and then further use it for RNA and DNA processes. The company was previously known as Biotec Pharmacon and is headquartered in Tromsø.
Læs mereMarkedsværdi
-
Aktieomsætning
-
Omsætning
112,62 mio.
EBIT %
2,5 %
P/E
-
Udbytteafkast, %
-
Finanskalender
7.5
2026
Delårsrapport Q1'26
28.5
2026
Generalforsamling '26
14.8
2026
Delårsrapport Q2'26
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
AZT: ArcticZymes Technologies strengthens IP platform with new patent grant supporting expansion into RNA therapeutics manufacturing
ArcticZymes Technologies strengthens IP platform with new patent grant supporting expansion into RNA therapeutics manufacturing
Bliv en del af Inderes community
Gå ikke glip af noget - opret en konto og få alle de mulige fordele
Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
